Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.45 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | RARB | P10826 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.45 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9170494 | 0.97 | TRPA1 (0.59) | TRPA1MAOAMAOBPTGS1PTGS2 | |
| SCHEMBL104511 | 0.97 | TRPA1 (0.59) | TRPA1MAOAMAOBPTGS1PTGS2 | |
| SCHEMBL24244793 | 0.91 | TRPA1 (0.53) | TRPA1MAOAMAOBPTGS1PTGS2 | |
| SCHEMBL13017113 | 0.91 | TRPA1 (0.53) | TRPA1MAOAMAOBPTGS1PTGS2 | |
| SCHEMBL8056212 | 0.85 | TRPA1 (0.48) | TRPA1MAOAMAOB | |
| SCHEMBL1131597 | 0.84 | PTGS1 (0.56) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL24827555 | 0.82 | TRPA1 (0.50) | TRPA1PTGS1PTGS2LMNACYP2C9 | |
| SCHEMBL5174938 | 0.81 | PTGS1 (0.54) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL18391826 | 0.80 | TRPA1 (0.44) | TRPA1MAOAMAOBHTR2ALOXL2 | |
| Ammonia Solution, Strong SCHEMBL7267232 | 0.79 | ESR1 (0.61) | TRPA1MAOAMAOBPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101704756-B | The synthetic method of 1-(4-fluorophenyl)-2-methyl-2-propylamine | 大连九信精细化工有限公司 | 2017-12-05 | — | — | CN | claimed |
| CN-101704756-A | Synthesis method of 1- (4-fluorophenyl) -2-methyl-2-propylamine | DALIAN KAIFEI FINE CHEMICALS C | 2010-05-12 | — | — | CN | claimed |
| CN-101704756-B | The synthetic method of 1-(4-fluorophenyl)-2-methyl-2-propylamine | 大连九信精细化工有限公司 | 2017-12-05 | — | — | CN | disclosed |
| CN-101704756-B | The synthetic method of 1-(4-fluorophenyl)-2-methyl-2-propylamine | 大连九信精细化工有限公司 | 2017-12-05 | — | — | CN | disclosed |
| US-9636375-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-9227940-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150005342-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-01-01 | — | — | US | disclosed |
| US-8889871-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140257773-A1 | METHOD OF PREDICTING TOXICITY OF CHEMICALS WITH RESPECT TO MICROORGANISMS AND METHOD OF EVALUATING BIOSYNTHETIC PATHWAYS BY USING THEIR PREDICTED TOXICITIES | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2014-09-11 | — | — | US | disclosed |
| US-20140163231-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-06-12 | — | — | US | disclosed |
| EP-1458392-A2 | ACRIDONE INHIBITORS OF IMPDH ENZYME | Bristol-Myers Squibb Company (US) | 2004-09-22 | — | — | EP | disclosed |
| CN-1158264-C | Metabotropic glutamate receptor antagonists for the treatment of central nervous system disorders | NPSҩ������˾ | 2004-07-21 | — | — | CN | disclosed |
| US-20040121964-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES | 2004-06-24 | — | — | US | disclosed |
| US-20040106559-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
| US-20040053955-A1 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-18 | — | — | US | disclosed |
| WO-2003059269-A2 | ACRIDONE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6429207-B1 | QUINOXALINE DERIVATIVES EXHIBITING A HIGH DEGREE OF POTENCY AND SELECTIVITY FOR INDIVIDUAL METABOTROPIC GLUTAMATE RECEPTORS (MGLUR) | NPS PHARMACEUTICALS, INC. | 2002-08-06 | — | — | US | disclosed |
| CN-1285820-A | Metabotropic glutamate receptor antagonists for the treatment of central nervous system disorders | NPS PHARMA INC (US) | 2001-02-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | TRPA1 4847/4885MAOA 636/4885MAOB 25/4885 |
| US-20040053955-A1 | Acridone inhibitors of IMPDH enzyme | IMPDH2, IMPDH1, XDH | TRPA1 4786/4885MAOA 182/4885MAOB 101/4885 |
| US-20150005342-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | TRPA1 4847/4885MAOA 636/4885MAOB 25/4885 |
| US-20040121964-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | TRPA1 3417/4885MAOA 3419/4885MAOB 3523/4885 |
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | GRM2, GRM1, GRM3 | TRPA1 694/4885MAOA 1463/4885MAOB 1393/4885 |
| US-20040106559-A1 | Hepatitis C virus inhibitors | HAVCR2, HCCS, RNASE1 | TRPA1 4863/4885MAOA 707/4885MAOB 103/4885 |
| US-20140163231-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | TRPA1 4847/4885MAOA 636/4885MAOB 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.